LAKE FOREST, Calif., March 11, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for the life sciences industry, serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers and reproductive medicine, today announced that it is co-sponsoring the Alliance for Regenerative Medicine 3rd Annual REGENMED Investor Day, to be held March 25, 2015 at the Metropolitan Club in New York City.
The one-day, high impact program provides institutional, strategic and venture investors with unique insight into regenerative medicine and advanced therapy-based treatments and tools. Clinical and commercial experts will be on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The event will also feature discussions with key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.
“We are excited to be an industry sponsor to this annual event organized by the Alliance for Regenerative Medicine,” stated Jerrell Shelton, Chief Executive Officer of Cryoport. “The participating and presenting companies play a vital role in the advancement of many new and potentially life-saving cell-based therapies. Cryoport offers validated and best-in-class cryogenic logistics solutions to support these important new developments in regenerative medicine. For example, we can support their logistics needs from early clinical trial distribution to commercialization strategies for allogeneic and autologous cell-based immunotherapies.”
According to a 2015 State of the Industry Briefing for regenerative medicine and advanced therapies given by ARM, there are 375 clinical trials in various stages of development and over 60 approved products in the space. A recent industry report states that the global market for regenerative medicine is expected to grow at a compound annual growth rate of 20% from 2014 to 2019. Cryoport is well positioned to become the logistics partner of choice in this growing market.
About Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine’s (ARM) mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.
Based in Washington, DC, ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare. For more information please visit www.alliancerm.org.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, pharmaceutical companies, contract manufacturers, and university researchers. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a 10 day dynamic shipment duration. Our information technology centers around our Cryoportal Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.
To download Cryoport’s investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company’s actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company’s cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2014. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Logo- http://photos.prnewswire.com/prnh/20140401/NY95107LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-co-sponsors-the-alliance-for-regenerative-medicine-3rd-annual-regenmed-investor-day-300048679.html
SOURCE Cryoport, Inc.
Help employers find you! Check out all the jobs and post your resume.
